Report of Foreign Issuer (6-k)

Share Name	Share Symbol	Market	Type
Elron Ventures Ltd (CE)	USOTC:ELRNF	OTCMarkets	Common Stock

FORM 6-K

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Report of Foreign Issuer

Pursuant to Rule 13a-16 or 15d-16

of the Securities Exchange Act of 1934

For the Month of November 2016

ELRON ELECTRONIC INDUSTRIES LTD.

(Translation of Registrant’s Name into English)

3Azrieli Center, Triangle Building, 42nd Floor, Tel Aviv • ISRAEL

(Address of Principal Corporate Offices)

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

Form 20-F þ Form 40-F ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ___

Indicate by check mark if the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934:

Yes o No ☐

If “Yes” is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-(2): 82-_______

English Translation of Registrant’s Investors Presentation filed with the Israeli Securities Authority on November 24, 2016

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	ELRON ELECTRONIC INDUSTRIES LTD. (Registrant)

	By:	/s/ Yaron Elad
		Yaron Elad
		VP & CFO

Dated: November 25, 2016

DISCOVER. INNOVATION November 2016 ELRON - INVESTOR PRESENTATION

Forward-Looking Information This presentation is for information purposes only. By this presentation, Elron does not intend to solicit offers to purchase its securities and the presentation does not constitute an invitation to receive such offers. Elron may make improvements and/or changes in the features or content presented herein at any time. Elron shall not be liable for any loss, claim, liability or damage of any kind resulting from the investor's reliance on or reference to any detail, fact or opinion presented herein. The presentation is not intended to provide a comprehensive description of Elron's activities, and Elron urges investors to consider the information presented herein in conjunction with its public filings including its annual and other periodic reports. Nothing in this presentation should be considered "investment advice", as defined in the Regulation of Investment Advice, Investment Marketing and Portfolio Management Law, 1995. Certain statements made over the course of this presentation may be forward-looking in nature, as defined in Section 21E of the U.S. Securities Exchange Act of 1934, and in Section 32A of the Israel Securities Law, 5728-1968. Such forward-looking statements involve known and unknown risks, uncertainties, forecasts, assessments, estimates or other information, which relates to a future event or matter whose occurrence is not certain and which is not within the sole control of Elron, and other factors which may cause the actual results, performance and achievements of Elron to be materially different from any future results, performance and achievements implied by such forward-looking statements. These forward looking statements are not proved facts and are based on Elron's subjective assessments which rely on analysis of general information, public publications, researches and reviews, which do not include any liability as to the accurateness or completeness of the information contained there and their accurateness hasn't been examined by Elron. The realization of these forward looking statements will be affected by factors that cannot be assessed in advance and which are not within the control of Elron. Elron assumes no obligation to update the information in this presentation and disclaims any obligation to publicly update or revise any such forward-looking statements to reflect any change in its expectations or in events, conditions, or circumstances on which any such statements may be based, or that may affect the likelihood that actual results will differ from those set forth in the forward-looking statements.These estimates, in whole or in part, may not materialize, or may materialize in a manner materially different than expected. The principal factors that may affect this are developments in Elron’s and its group companies’ fields of operation; failure to obtain regulatory approvals; failure to meet goals; failure or delay in recruiting the number of patients or samples necessary to complete clinical trials; failure or delay in correcting defects or the discovery of additional defects; clinical trial results; inability to realize technologies; modifications in technologies; modifications in work plan, goals and/or strategy; or if any risk associated with Elron and its group companies and the course of clinical trials and their results occurs. 2

This slide contains forward-looking information as defined in Section 21E of the U.S. Securities Exchange Act of 1934, and in Section 32A of the Israel Securities Law, 5728-1968. See Slide 2 of this presentation. RECENT DEVELOPMENTS Dividend: $15 MILLION DISTRIBUTION TO SHAREHOLDERS Medical Devices: NEW INVESTMENT IN NITINOTES + Nitinotes is developing an endoscopic gastric sleeve procedure for the treatment of obesity+ Our investment: $3m; our holding: 36%* + Since 2010, dividends to shareholders amounted to $140m CartiHeal: FDA APPROVAL TO INITIATE A CLINICAL STUDY IN THE U.S. + The FDA approved CartiHeal’s IDE application to conduct a clinical trial for U.S. marketing approval of the Agili -C+ The Agili-C is an implant for cartilage & bone repair in loadbearing joints, such as the knee OpenLegacy: FINANCING ROUND JOINED BY NEW INVESTORS + OpenLegacy closed a ~$5m financing from external investors+ OpenLegacy received an honorable mention by Gartner Magic Quadrant Full Lifecycle API Management, October 2016 3 * 36% after the funding round will be completed; currently 14%

This slide contains forward-looking information as defined in Section 21E of the U.S. Securities Exchange Act of 1934, and in Section 32A of the Israel Securities Law, 5728-1968. See Slide 2 of this presentation. 2017: IMPORTANT EVENTS 4 Complete patient recruitment for FDA trial BRAINSGATE Complete FDA trial on UTI (urinary tract infection) application POCARED Commence FDA trial following approval of IDE application CARTIHEAL Go-to-market based on new management’s work plan NOTAL VISION

DISCOVER. ELRON

OPERATIONAL HOLDING COMPANY IN THE VC SPACE WE SPECIALIZE IN MEDICAL DEVICE TECHNOLOGIES WITH SIGNIFICANT EXIT POTENTIAL + WE HAVE 50 YEARS EXPERIENCE IDENTIFYING OPPORTUNITIES, BUILDING TECHNOLOGY LEADERS, AND EXITING HOLDINGS + WE INVEST PRIMARILY IN EARLY STAGE COMPANIES+ WE RELY ON A PROVEN STRATEGY OF HANDS-ON INVOLVEMENT IN THE DAY-TO-DAY OPERATIONS OF OUR GROUP COMPANIES+ OUR COMPANIES BENEFIT FROM OUR SKILL AT TAKING AN IDEA THROUGH R&D & REGULATION, WHILE CREATING MAJOR VALUE Elron was established in 1962 THE IDEA: to bridge the gap between Israeli R&D and industry, and create “a knowledge-based industry” (later named hi-tech…) 6

PERFORMANCE IN 2016: 114 20 59 4 269 * Including RDC * 26

LOSS (1-9/16): $17.5M INVESTMENTS *: $40M PERFORMANCE IN 2016: 20 59 4 269 * Including RDC 7 LIQUID RESOURCES *: $89M 26 SINCE 2010: AGGREGATE PROFIT OF $151M; $140M IN DIVIDENDS 114

LOSS (1-9/16): $17.5M INVESTMENTS *: $40M PERFORMANCE IN 2016: 114 20 59 4 269 * Including RDC 7 LIQUID RESOURCES *: $89M 26 SINCE 2010: AGGREGATE PROFIT OF $151M; $140M IN DIVIDENDS

VALUE POTENTIAL 1 Includes Elron’s direct holdings and its effective indirect holdings through RDC and RDSeed. Includes investments made after Sept. 30, 2016.2 Includes Elron’s balance and 50.1% of RDC’s balance.3 The above financial data are based on publicly available information and do not represent a valuation, investment advice, or a financial opinion of any kind. Holdings in companies 1 Book value at Sept. 30, 2016 ($m) Amount invested ($m) Associates and consolidated companies: Pocared (61%) 17.9 59.9 BrainsGate (30%) 3.8 29.1 CartiHeal (35%) 4.4 11.7 PLYmedia (23%) - 2.5 Others 12.9 20.3 Companies presented at fair value: Notal Vision (21%) 17.9 12.3 Others 4.6 18.6 Total Holdings 61.5 154.4 Fair value of contingent consideration from sale of companies 2 4.5 4.5 Cash (as of Nov. 22, 2016) 2 36.0 36.0 Financial assets, net (as of Nov. 22, 2016) 2 27.7 27.7 TOTAL 3 129.7 222.6 Price per share on TASE (in $) (as of Nov. 22, 2016) 4.55 Elron’s market value (as of Nov. 22, 2016) 135.4 8 SUMMARY OF OUR ASSETS:MARKET VALUE LESS CASH AND FINANCIAL ASSETS = $72M

DISCOVER. BRAINSGATE

BRAINSGATE ESTABLISHED: 2000FIRST INVESTMENT: 2005TOTAL INVESTMENT: $96MMAIN PARTNERS: Johnson & Johnson, Boston Scientific, Medtronic, Pitango, Cipio Partners VISION: To increase the potential number of stroke victims who receive treatment from ~7% to ~80%PRODUCT: Electrode used to electrically stimulate a nerve center behind the nasal cavity (the SPG), to induce dilation of cerebral blood vessels and increase blood flow to the brain OUR INVESTMENT:$29M OUR HOLDING:30% 10

~800,000 PEOPLE SUFFER A STROKE EACH YEAR IN THE U.S. STROKE: INTERRUPTION OF BLOOD FLOW TO THE BRAIN When blood flow to an area of the brain is cut off blood cells begin to dieWhen brain cells die, functions controlled by that part of the brain (e.g. memory, muscle control) are lostTHE EFFECTS OF A STROKE DEPEND ON HOW MUCH DAMAGE TO THE BRAIN OCCURRED THERE ARE 2 TYPES OF STROKE. ISCHEMIC STROKE Blood flow to the brain is blocked by a blood clot87% of strokes are ischemicBRAINSGATE’S DEVICE IS INTENDED TO TREAT ISCHEMIC STROKE HEMORRHAGIC STROKE Blood leaks into the brain from a ruptured blood vessel13% of strokes are hemorrhagic Sources: American Heart Association: Heart Disease and Stroke Statistics Report – 2015; BrainsGate website: http://brainsgate.com/eng/page.php?id=3&instance_id=9. 11

THE COST OF STROKE EACH YEAR IN THE U.S.: $34 BILLION Sources: American Heart Association: Heart Disease and Stroke Statistics Report – 2010, 2015; CDC website: http://www.cdc.gov/stroke/facts.htm. 15-30% OF STROKE SURVIVORS ARE LEFT PERMANENTLY DISABLED mRS Average Lifetime Cost Per Stroke Patient Sources: Samsa et al, Performing Cost-Effectiveness Analysis by Integrating Randomized Trial Data with a Comprehensive Decision Model: Application to Treatment of Acute Ischemic Stroke, J Clin Epidemiol Vol. 52, No. 3, pp. 259–271, 1999Savings calculated by: Expected mRS Distribution X Effect X Tx Cost Savings 0 1 2 3 4 5 6 mRS: measure of degree of disability of stroke patients (0=complete recovery, 6=death) 12

WHY ARE SO MANY STROKE SURVIVORS LEFT DISABLED? THE GOAL OF ALL STROKE TREATMENTS IS TO RESTORE BLOOD FLOW TO THE AFFECTED AREA AS QUICKLY AS POSSIBLE, AND PREVENT BRAIN CELL DEATH Cells in the affected area die almost immediately, and cannot be salvagedHowever, surrounding the blockage are regions of viable tissue at risk – the ischemic penumbra – which can be salvaged if blood flow is restored in time  DRUG TREATMENT FOR RESTORING BLOOD FLOW TO THE AFFECTED AREA IS AVAILABLE, BUT ONLY ~7% OF STROKE VICTIMS RECEIVE IT, AS SAFETY FACTORS LIMIT THE TREATMENT WINDOW TO 4.5 HOURS Source: American Heart Association: Temporal Trends in Patient Characteristics and Treatment With Intravenous Thrombolysis Among Acute Ischemic Stroke Patients at Get With the Guidelines–Stroke Hospitals, Schwamm, Circ Cardiovasc Qual Outcomes. 2013;6:543-549. 13

tPA: THE ONLY FDA APPROVED DRUG TREATMENT SINCE 1996 THE GOAL OF ALL STROKE TREATMENTS IS TO RESTORE BLOOD FLOW TO THE AFFECTED AREA AS QUICKLY AS POSSIBLE, AND PREVENT BRAIN CELL DEATH CLOT-BUSTING DRUG 1 CLOT RETRIEVING DEVICES 2 ELECTRICAL STIMULATION 3 tPA: 4.5-HOUR TREATMENT WINDOWThe risk of hemorrhage just 3 hours after stroke onset increases 10XCertain patients are eligible for treatment up to 4.5 hours after symptoms first starttPA is not approved for use after 4.5 hours from stroke onsetMOST PATIENTS DO NOT GET TO THE HOSPITAL IN TIME FOR tPA TREATMENT, DUE IN PART TO FAILURE TO RECOGNIZE SYMPTOMS AND DISTANCE FROM HOME-TO-HOSPITAL Sources: Adams HP, et al (2003) Stroke 34, 1056-83; del Zoppo GJ, et al (2009) Stroke 40, 2945-48. 14

THE GOAL OF ALL STROKE TREATMENTS IS TO RESTORE BLOOD FLOW TO THE AFFECTED AREA AS QUICKLY AS POSSIBLE, AND PREVENT BRAIN CELL DEATH CLOT-BUSTING DRUG 1 CLOT RETRIEVING DEVICES 2 ELECTRICAL STIMULATION 3 CLOT RETRIEVERS: ADD-ON TREATMENTIn the past this treatment was used in an 8-hour treatment window, but was not widely adopted due to lack of proven clinical benefit2015: Several large multicenter trials were published showing that treatment with endovascular treatment in a limited time window has significant clinical benefits for stroke patientsTHIS MODE OF TREATMENT IS EXPECTED TO GRADUALLY INCREASE THE NUMBER OF STROKE VICTIMS WHO RECEIVE TREATMENT Sources: Broderick JP, et al (2013) New England Journal of Medicine 368(10), 893-903; Ciccone A, et al (2013) New England Journal of Medicine 368(10), 904-13; Kidwell CS, et al (2013) New England Journal of Medicine 368(10), 914-23; Berkhemer OA, et al (2015) New England Journal of Medicine 372(1), 11-20; Campbell BC, et al (2015) New England Journal of Medicine 372(11), 1009-18; Goyal M, et al (2015) New England Journal of Medicine 372(11), 1019-30; Joven TG, et al (2015) New England Journal of Medicine; Saver JL, et al (2015) New England Journal of Medicine; European Stroke Organisation (ESO) Conference 2015. Abstract 82, Abstract 180. ENDOVASCULAR THERAPY: AN EFFECTIVE TREATMENT BASED ON RECENT STUDIES 15

BRAINSGATE: ALTERNATE THERAPY THAT EXPANDS THE TREATMENT WINDOW TO 24 HOURS THE GOAL OF ALL STROKE TREATMENTS IS TO RESTORE BLOOD FLOW TO THE AFFECTED AREA AS QUICKLY AS POSSIBLE, AND PREVENT BRAIN CELL DEATH CLOT-BUSTING DRUG 1 CLOT RETRIEVING DEVICES 2 ELECTRICAL STIMULATION 3 ELECTRODE: 24-HOUR TREATMENT WINDOWElectrical stimulation of the SPG (a nerve center behind the nasal cavity) using a miniature electrodeThe electrode’s activation induces dilation of cerebral blood vessels, and augments cerebral blood flow; without affecting central blood pressure THE RISK OF HEMORRHAGE IS NOT INDUCED, THEREFORE THE TREATMENT MAY BE GIVEN DURING A BROAD WINDOW OF UP TO 24 HOURS 16

ISS: THE ISCHEMIC STROKE SYSTEM BrainsGate’s ISS is an investigational device, not approved for marketing. GuideView SPG (sphenopalatine ganglion) = supplies parasympathetic innervation to the anterior cerebral circulation and some of the posterior circulationTransmitter = emits RF waves which energize the implantImplant = delivers electrical pulses to the SPGGuideView = helps navigate the implant through the canal to its correct position near the SPG using a patient’s CT TREATMENT REGIMEN:5 daily stimulation sessions, of 4 hours eachThe neurologist performs the implantation (which is brief and simple), with the aid of a navigation system 17

STATUS 18 This slide contains forward-looking information as defined in Section 21E of the U.S. Securities Exchange Act of 1934, and in Section 32A of the Israel Securities Law, 5728-1968. See Slide 2 of this presentation. BRAINSGATE IS CONDUCTING AN FDA TRIAL FOR U.S. MARKETING APPROVAL OF THE ISS, ON 800-1000 PATIENTS: APR ‘14 Green light from DSMB (Data Safety and Monitoring Board) to continue the trial based on an interim analysis of the safety results of 350 patients MAY ‘16 Green light from DSMB to continue the trial based on a second (and final) interim analysis of 600 patients AUG ‘16 First implantation with new injectable implant JUN ‘11 FDA trial commences 2017 Patient recruitment expected to be completed (as of Nov ‘16, ~680 patients recruited)

DISCOVER. POCARED

POCARED ESTABLISHED: 2004FIRST INVESTMENT: 2007TOTAL INVESTMENT: $107MMAIN PARTNER: SCP Vitalife VISION: To promote antibiotic stewardship and significantly reduce lab costs by providing a method for rapid infectious diseases diagnosticsPRODUCT: Rapid and automated microbiology lab system for infectious diseases diagnosis OUR INVESTMENT:$64M OUR HOLDING:67% 20

AUTOMATED LAB SYSTEM: THE DIAGNOSTICS OF TOMORROW In the 21st century, POCARED developed a technology for automatically identifying bacteria in body fluids, by identifying their optical “fingerprint” RAPID & AFFORDABLE TESTING THE METHODS USED IN ORGANISM IDENTIFICATION HAVEN’T CHANGED IN MORE THAN 100 YEARS BACTERIA CULTURING: THE DIAGNOSTICS OF YESTERDAY Since the 19th century, microbiology testing has been done by culturing bacteria in petri dishes Expensive: Requires reagents and skilled lab techniciansManual: Prone to human error, limited throughputInefficient: Large lab footprintLengthy: Diagnosis that relies on culturing bacteria to reach sufficient concentration levels takes days Over-/mis-prescribing antibiotics while awaiting lab results (promotes antibiotic resistance)Costly lab tests CONSEQUENCES 21

“Few issues in public health today are as critical and time urgent as combating the growing threat of antibiotic resistance” (Margaret A. Hamburg, M.D., Commissioner of the FDA, 2009-2015) “ ” HOW DOES ANTIBIOTIC RESISTANCE HAPPEN? The use of antibiotics is the single most important factor leading to antibiotic resistance around the worldAntibiotics are among the most commonly prescribed drugsUp to 50% of all the antibiotics prescribed are not needed or are not optimally effective as prescribed 2,000,000ILLNESSES EACH YEAR IN THE U.S. 23,000DEATHS EACH YEAR IN THE U.S. $20BANNUAL EXCESS DIRECT U.S. HEALTHCARE COSTS $35BANNUAL U.S. SOCIETAL COSTS FOR LOST PRODUCTIVITY penicillin 1943 1940 tetracycline erythromycin methicillin gentamicin vancomycin imipenem ceftazidime levofloxacin linezolid daptomycin ceftaroline 1950 1959 1953 1968 1960 1962 1972 1979 1972 1988 1985 1998 1985 1987 1996 1996 2000 2001 2003 2004 2010 2011 TIMELINE OF DEVELOPING ANTIBIOTIC RESISTANCE Antibiotic introduced Resistance identified WHAT ARE THE CONSEQUENCES? Sources: CDC, Antibiotic Resistance Threats in the United States, 2013; “FDA’s Take on the Executive Order and National Strategy to Combat Antibiotic-Resistant Bacteria”, posted on September 18, 2014 by FDA Voice, http://blogs.fda.gov/fdavoice. 22

THE MICROBIOLOGY LAB: THE LAST LAB TO IMPLEMENT FULL AUTOMATION Sources: Bourbeau PP and Ledeboer NA (2013) Journal of Microbiology 51(6), 1658-65; Kaplan RL and Burgess TE (2010) Journal of Microbiology & Biology Education 11(2), 140-43; Novak SM and Marlowe EM (2013) Clinics in Laboratory Medicine 33, 567-88. THERE IS A DEMAND FOR AN AUTOMATED MICROBIOLOGY LAB WITH THE PROMISE FOR:  FEWER SKILLED WORKERS  HIGHER THROUGHPUT  GREATER EFFICIENCY          The average age of the lab workforce in the U.S. is about 50, and increasingAbout 70% of training programs have closed in the U.S. over the last 40 years Testing volumes are increasing 10-15% per year, due to factors such as:technological innovation, aging population, infection control legislation, and more  Economic pressures drive the need to contain costs while maintaining high accuracy:“DO MORE WITH LESS”  23

STEP 1: SAMPLE PREPARATIONFiltration using “wet foam” technology to isolate micro-organisms STAGE 3: REPORTINGA report with data on specimen screening (positive/negative), organism identification and enumeration is received STEP 2: FLUORESCENCE ANALYSIS The Analyzer employs algorithms that determine which wavelength to choose, and detect the organism’s “optical fingerprint” P-1000 Analyzer Sample Processor User interface POCARED’S AUTOMATED LAB SYSTEM A DIAGNOSTIC TEST BASED ON OPTICAL TECHNOLOGY + Micro-organisms are identified based on their unique optical signatures in response to different UV wavelengths + Culture-free, lab assistant operated + Gold standard accuracy + A full batch of 42 samples takes 2 hours to diagnose The P-1000 Analyzer is investigational in the U.S., and CE-marked in the EU. The Sample Processor is exempt from regulatory approvals. 24

The Analyzer employs algorithms that determine which wavelength to choose, and detect the organism’s “optical fingerprint” P-1000 Analyzer Sample Processor User interface The P-1000 Analyzer is investigational in the U.S., and CE-marked in the EU. The Sample Processor is exempt from regulatory approvals. *

STATUS 25 This slide contains forward-looking information as defined in Section 21E of the U.S. Securities Exchange Act of 1934, and in Section 32A of the Israel Securities Law, 5728-1968. See Slide 2 of this presentation. FIRST APPLICATION – Diagnosis of urinary tract infection Pocared is preparing to conduct a new FDA trial, planned for 2017 SECOND APPLICATION – Rapid antibiotic susceptibility test Pocared is currently conducting clinical proof-of-concept

THE NEXT APPLICATIONS FOR POCARED’S P-1000: Source: Pocared data. ANTIBIOTIC RESISTANCE(rapid AST)NO rapid solution currently availableSTATUS: clinical feasibility THROAT SWABS(streptococci)41m tests in the U.S. annuallySTATUS: clinical validation, ready for regulatory studies NASAL SWABS(MRSA/MSSA)8m tests in the U.S. annuallySTATUS: clinical feasibility BLOOD CULTURES(sepsis)50m tests in the U.S. annuallySTATUS: clinical proof of concept 1 3 2 4 26 This slide contains forward-looking information as defined in Section 21E of the U.S. Securities Exchange Act of 1934, and in Section 32A of the Israel Securities Law, 5728-1968. See Slide 2 of this presentation.

DISCOVER. CARTIHEAL

CARTIHEAL ESTABLISHED: 2009FIRST INVESTMENT: 2012TOTAL INVESTMENT: $30MMAIN PARTNERS: Johnson & Johnson, Accelmed VISION: To treat joint surface lesions, and to halt the progression of knee osteoarthritis and delay or prevent knee replacementPRODUCT: Implant for cartilage and bone repair in the joint OUR INVESTMENT:$12M OUR HOLDING:35% 28

29 CARTILAGE DEFECTS ARE PAINFUL AND IMPAIR PHYSICAL ACTIVITY CARTILAGE DEFECTS LEFT UNTREATED MAY PROGRESS TO OSTEOARTHRITIS  No current treatment has succeeded in regenerating native cartilage Cartilage does not possess spontaneous healing potential There are no treatments that halt the progression of osteoarthritis (OA) Patients who do not respond to pain relievers and are not yet candidates for knee replacement lack a solution KNEE PROCEDURES IN THE U.S. During 2004-2011 ~2 million people underwent a surgical procedure addressing a cartilage defect in the kneeThe most common procedures: microfracture and debridement In 2010 ~720,000 total knee replacements were performedPersons with knee OA spend ~50% of their postdiagnosis life expectancy in between treatments while waiting for total knee replacement Sources: CDC website: http://www.cdc.gov/arthritis/basics/osteoarthritis.htm, http://www.cdc.gov/nchs/fastats/inpatient-surgery.htm; Losina E, et al (2015) Arthritis Care & Research 67(2), 203-15; McCormick F, et al (2014) Arthroscopy 30(2), 222-26. OSTEOARTHRITIS AFFECTS ~14% OF ADULTS AGED 25 YEARS AND OLDER IN THE U.S.

30 12 weeks post-op 6 weeks post-op 3 weeks post-op The implant has a unique structure, composed of calcium carbonate with hyaluronic acid The Agili-C is investigational in the U.S., and CE-marked in the EU. AGILI-C: IMPLANT FOR CARTILAGE & BONE REPAIR IN JOINTS

STATUS 31 This slide contains forward-looking information as defined in Section 21E of the U.S. Securities Exchange Act of 1934, and in Section 32A of the Israel Securities Law, 5728-1968. See Slide 2 of this presentation. CARTIHEAL’S AGILI-C HAS BEEN IMPLANTED IN ~200 PATIENTS TO DATE TO TREAT TRAUMATIC AND DEGENERATIVE LESIONS IN THE KNEE, GREAT TOE & ANKLE 2016 The FDA approved CartiHeal’s IDE application to conduct a clinical trial for U.S. marketing approval of the Agili -C

DISCOVER. NOTAL VISION

NOTAL VISION ESTABLISHED: 2000FIRST INVESTMENT: 2002TOTAL INVESTMENT: $55MMAIN PARTNERS: Ganot, Evergreen VISION: To save the eyesight of Age-related Macular Degeneration (AMD) patientsPRODUCT: Home-monitoring system that sends out an alert when a change for the worse is detected in the condition of dry AMD patients OUR INVESTMENT:$12M OUR HOLDING:21% 33

AMD: AGE-RELATED MACULAR DEGENERATION AMD destroys sharp, central vision, necessary for common tasks such as facial recognition, driving, reading, & watching television SUDDEN AND DEVASTATING DISEASE AMD has 2 stages: “dry” (non-neovascular) and “wet” (neovascular)~90% of blindness due to AMD is associated with the wet stageAMD PROGRESSES FROM THE DRY STAGE TO THE WET STAGE SILENTLY AND VISION LOSS OCCURS RAPIDLY (WITHIN WEEKS) AMD: THE LEADING CAUSE OF BLINDNESS IN THE ELDERLY POPULATION IN THE WESTERN WORLD Sources: Brown DM, et al (2006). New England Journal of Medicine 355, 1432-44; Slakter JS & Stur M (2005). Survey of Ophthalmology 50, 263-73; Gehrs KM, et al (2006). Annals of Medicine 38, 450-71; Ferris FL, et al. (1984) Archives of Ophthalmology,102(11), 1640-42; Notal Vision website: http://www.foreseehome.com/wet-amd.html. 34

~9.1M INDIVIDUALS WITH DRY AMD IN THE U.S. ARE AT RISK OF CONVERSION TO WET AMD THE NEED FOR HOME MONITORING It is not possible to predict who will develop wet AMD, and if so, whenDry AMD patients are monitored once or twice a year, in routine check-ups at the eye doctorWet AMD can be treated, but due to late diagnosis, 64% of eyes end with dysfunctional vision even after treatment Sources: Wittenborn JS & Rein DB. “The Future of Vision: Forecasting the Prevalence and Cost of Vision Problems.” NORC at the University of Chicago. Prepared for Prevent Blindness, June 11, 2014; The CATT Research Group: Baseline Predictors for One-Year Visual Outcomes with Ranibizumabor Bevacizumabfor Neovascular Age-related Macular Degeneration. Ophthalmology 2012. ForeseeHome: a 3-min home eye exam  The device is easy to use (“plug & play”) The patient takes a brief daily test The system detects visual changes before symptoms appear The Call Center alerts the patient and doctor when the disease progresses 35

FORESEEHOME: SAVING THE PATIENT’S VISION BEFORE IT’S TOO LATE FDA CLEAREDCE MARKEDCLINICALLY PROVENMEDICARE COVERAGEADOPTED IN THE AAOS’s CLINICAL GUIDELINES MORE THAN 2,000,000 TESTS TO DATE PROVEN PREVENTION OF VISION LOSSAREDS2: Notal Vision conducted a trial in collaboration with the NIH on 1,520 patients in 44 eye clinics:94% of patients who used the device as directed preserved functional vision at diagnosis vs only 62% of patients using other detection methods 36

STATUS 37 This slide contains forward-looking information as defined in Section 21E of the U.S. Securities Exchange Act of 1934, and in Section 32A of the Israel Securities Law, 5728-1968. See Slide 2 of this presentation. BUILDING A COMPANY: 1 Recruited new CEO – Quinton Oswald, formerly of SARCode (acquired by Shire Pharmaceuticals), Genentech, and Novartis 2 Strategy and go-to-market analysis have been completed 3 Scale-up work plan in place 4 Relocated to U.S.; new management recruited

DISCOVER. CLOUDYN

CLOUDYN ESTABLISHED: 2011FIRST INVESTMENT: 2011TOTAL INVESTMENT: $18MMAIN PARTNERS: InfoSys, Carmel Ventures, Titanium Investments VISION: To enable enterprises to fully realize their cloud potentialPRODUCT: SaaS tools for monitoring and optimizing hybrid cloud costs and usage OUR INVESTMENT:$6M OUR HOLDING:40% 39

~80% OF ENTERPRISES HAVE HYBRID CLOUD ENVIRONMENTS 40 Source: ScienceLogic Annual Report on Hybrid IT Trends, http://www.sciencelogic.com/cloud-adoption-survey/ THE PROBLEM:62% OF HYBRID CLOUD MANAGERS HAVE LITTLE VISIBILITY | 52% DON’T HAVE A WAY TO DETERMINE WHAT THEY ARE PAYING FOR | 75% DON’T HAVE A WAY TO CONTROL THEIR CLOUD SPRAWL THE CHALLENGE: WORKLOAD MIGRATION CLOUD OPERATION CONTINUOUS OPTIMIZATION Migrating the proper workloads and building the right mix of clouds is tough Enterprises are struggling to build a single, accurate picture to govern cloud resource usage Cost and performance inefficiencies reduce cloud transformation ROI

CLOUDYN PROVIDES UNPRECEDENTED INSIGHTS DERIVED FROM OPERATIONAL & FINANCIAL METRICS 41 THE SOLUTION: VISIBILITY Cloudyn’s solutions enable enterprises to gain granular, real-time visibility into consumption, cost & performance of multi-platform hybrid clouds ACCOUNTABILITY Cloudyn empowers enterprise-wide cloud accountability through accurate and reliable cost allocation and chargeback OPTIMIZATION Cloudyn provides businesses with optimized recommendations for maintaining the most efficient deployment, both cost- and performance-wise Cloudyn monitors: 8,000 cloud apps 300,000 concurrent virtual machines (VMs)

CLOUDYN RAISES $4M FROM INFOSYS 42

DISCOVER. OPENLEGACY

OPENLEGACY ESTABLISHED: 2013FIRST INVESTMENT: 2014TOTAL INVESTMENT: $8.5MMAIN PARTNERS: Entrepreneurs VISION: To deliver any core application as a digital servicePRODUCT: Tools that rapidly extract the services and information from legacy systems, and automatically transform them into mobile, web, & cloud applications OUR INVESTMENT:$5.2M OUR HOLDING:45% 44

45 NUMEROUS ENTEPRISES RUN ON IT SYSTEMS THAT ARE FROZEN IN TIME LEGACY SYSTEM = AN OUTDATED COMPUTER SYSTEM, SOMETIMES DATING BACK TO THE 1970s-1980s WHY DO ENTERPRISES RELY ON OUTDATED IT SYSTEMS FOR CRITICAL APPLICATIONS? Legacy systems preserve valuable business knowledgeReplacing/upgrading IT systems involves significant costs and risks (security, compatibility, data loss)While replacing/upgrading legacy systems is highly complex, documentation is poor and skill with these systems in short supply    THE COST OF MAINTAINING LEGACY SYSTEMSIn both the public and private sectors in the U.S. (e.g. federal agencies & banks), maintaining legacy systems consumes three-quarters of IT budgets Sources: United States Government Accountability Office, Information Technology: Additional Actions and Oversight Urgently Needed to Reduce Waste and Improve Performance in Acquisitions and Operations, GAO-15-675T, Jun 10, 2015, http://www.gao.gov/assets/680/670745.pdf; Tenemos, Banks are stuck in spaghetti junction, Aug 20, 2015, https://www.temenos.com/en/market-insight/retail-insight/banks-are-stuck-in-spaghetti-junction/

46 OPENLEGACY: INSTANT DELIVERY OF ENTERPRISE CORE APPLICATIONS AS DIGITAL SERVICES AT A FRACTION OF THE COST OPENLEGACY REVOLUTIONIZES LEGACY MODERNIZATION, OFFERING INDEPENDENCE FROM EXPENSIVE VENDORS, AND ELIMINATING HIGH COSTS AND HIGH RISK Reduced time to market (TTM) A fraction of the cost (TCO) Ensures success of digital transformation GENERATES APIs IN MINUTES INSTEAD OF MONTHS ELIMINATES THE NEED FOR A COMPLEX TECHNOLOGY STACK UNLIMITED FLEXIBILITY DRAMATICALLY REDUCES RISK OF FAILURE    OpenLegacy received an honorable mention by Gartner Magic Quadrant Full Lifecycle API Management, October 2016

OUR CYBER COMPANIES 47 IRONSCALESProtecting enterprises from cyber phishing attacks27% by RDCOur investment: $1.5m SIXGILLCyber intelligence platform that analyzes the dark web22%Our investment: $2.5m SECUREDTOUCHReal time identity verification for mobile apps and mobile websites29% by RDCOur investment: $2.2m ALCIDESecurity and management tools for hybrid data centers30%Our investment: $1.5m SECDOAutomatic detection and investigation of security alerts24% by RDCOur investment: $4m NEW!

ELRON. OPPORTUNITY Thank you.elron.com

Market Data

News

Trading Tools

Markets

Discover

Hot Features

Follow Feed

Options Flow

Monitor

ELRNF Elron Ventures Ltd (CE)